ÂÜÀòÂÒÂ×

Paul Kaplan, PhD, MBA has a diverse work experience spanning several decades. Paul is currently serving as the Vice President of Development Operations at Tevard Biosciences since May 2023. In this role, they are responsible for advancing the development portfolio and managing various aspects of program governance, portfolio planning, and program tracking.

Prior to this, Paul worked at CRISPR Therapeutics from 2017 to 2022 as the Executive Director of Program Management. Here, they led critical component manufacturing teams, supervised cross-functional teams involved in filing INDs for first-in-man gene editing therapeutics, and played a key role in designing and building a GMP cell therapy manufacturing facility.

From 2015 to 2017, they served as the Head of Project Planning & Operations at Alzheon, Inc. In this position, Paul led the re-formulation and manufacturing effort for an oral Alzheimer's Disease therapeutic, prepared and filed CTA for another oral Alzheimer's Disease therapeutic, and led the vendor selection team for Phase 1 CRO.

Between 2000 and 2015, Paul worked at Genzyme Corporation as a Senior Director of Program Management. Paul held various positions at Creative Biomolecules from 1990 to 2000, and prior to that, they served as an Assistant Professor at Harvard Medical School/Dana Farber Cancer Institute.

Paul's career began at the Salk Institute for Biological Studies where they worked as a Fellow from 1982 to 1987. Overall, Paul Kaplan's extensive experience in various biotech companies and academic institutions demonstrates their expertise in program and project management, as well as their commitment to advancing novel therapies for serious diseases.

Paul Kaplan, PhD, MBA has a PhD in Microbiology from the University of Texas Southwestern Medical School. Paul also holds an MBA from Northeastern University. Prior to these degrees, they obtained an AB in Biology from the University of Pennsylvania.